THERAmolecular

DRUG-PORTAL
password protected

Our Mission: At THERAmolecular, LLC we are dedicated to the discovery and design of safe and effective therapeutics for a range of human and animal diseases. We pursue this goal by harnessing state-of-the-art CADD methods and strategies, including advanced bioinformatics, cheminformatics and machine learning approaches.

Our Business Model: We are experienced research scientists dedicated to the basic science of early-stage drug discovery and design. We draw a distinction between the fundamental science of drug-discovery, including target identification, molecular design, synthetic routes, ADMET predictions and so forth, from downstream aspects of drug development and deployment, including animal model trials, human clinical trials, FDA approval and product marketing.
Our early-stage expertise includes...

disease/target selection
drug design using multiple strategies
drug (hit) candidate optimization
drug prospectus development
provisional patenting/trade secret filings
direct marketing to biopharma community
technical assistance with drug transfer

Leveraging Technological Advancements: No longer is drug discovery confined solely to the realm of deep-pocket pharmaceutical giants. Rapid advances in technology have democratized, diversified and empowered micro-companies (like THERAmolecular) to catalyze and accelerate early-stage discovery of novel drugs with a very reasonable chance of entering clinical trial. These technological advances include artificial intelligence and machine learning, faster computers, cloud computing, rapidly evolving drug-design software and improved understanding of chemistry and molecular physics at the quantum level. We do not view our role as developers of these technologies; rather, we review and evaluate new software algorithms and applications for speed, accuracy, reliability and cost/benefit.